DM RWE provided financial support for a non-profit research in oncology
DM RWE made a financial contribution to a research program in oncology by the Foundation for Cancer Research Support (RakFond). The funds will be used to finance a research project run by promising scientists.
The Foundation’s team of researchers have already achieved many profound scientific breakthroughs, making a significant contribution to clinical practice and changing approaches to diagnosis and treatment of cancerous diseases. This makes it even more necessary to provide sufficient financing for the future development of oncology.
“Despite huge progress, cancer is still one of the main causes of death worldwide. Therefore, securing substantial funding for the research in this field plays a critical role. We understand that everyone's contribution is a joint contribution to the global fight against cancer.” - Alexey Loleit, Chief Strategy and Product Officer at DM RWE.
With the support and investment in cancer research, much has been achieved over the past few years:
- The oncological mortality rate is gradually decreasing;
- over 150 new antitumor drugs or indications have been approved by the American Food and Drug Administration (FDA) since 2006;
- two out of three people with cancer now live at least 5 years after being diagnosed.
“Despite many successes, cancer still needs to be studied more closely. And the feasibility of research projects depends directly on funding. New projects and innovative ideas are followed by the development of breakthrough methods and means of cancer prevention, diagnostics and treatment,” – added Kristina Zakurdayeva, the founder and Chair of the Foundation for Cancer Research Support.
Reports on all supported projects of Rakfond are publicly available and are published at https://www.rakfond.org/reports/